This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Analysts initiated bullish coverage on IAM, AMRO, CWH, SUPN, issuing Buy, Outperform or Overweight ratings with price targets.
Stocks · News reference
B of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Piper Sandler Resumes Supernus Pharmaceuticals at Overweight
Piper Sandler resumed coverage of Supernus Pharmaceuticals with an overweight rating, highlighting the strategic benefits of the company's merger with Indivior.
Why Indivior Pharmaceuticals Stock Topped the Market Today
Indivior Pharmaceuticals completed its merger with Supernus Pharmaceuticals on November 2, 2026, creating a leading CNS biopharmaceutical company. The combined entity will operate under the Supernus name and ticker, with Indivior shareholders receiving a $1 billion special cash dividend and owning approximately 56.5% of the merged company. The merger aims to achieve $125 million in annual cost synergies.
Supernus Secures $650 Million Senior Secured Term Loan
Supernus Pharmaceuticals entered into a $650 million senior secured term loan agreement with Citibank and other lenders to support its merger and general corporate needs.
8-K filing — SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Filed: 2026-11-02 AccNo: 0001104659-26-121103 Size: 187 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Supernus Pharmaceuticals Completes Merger with Indivior Pharmaceuticals
Supernus Pharmaceuticals, Inc. has finalized its merger with Indivior Pharmaceuticals, Inc., forming a new, diversified biopharmaceutical company operating as Supernus, Inc.